Brancale, Andrea ORCID: https://orcid.org/0000-0002-9728-3419, Vlachakiis, Dimitros, Kandil, Sahar, Biondaro, Sonia, Berry, Colin ORCID: https://orcid.org/0000-0002-9943-548X and Neyts, Johan 2008. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Antiviral Research 78 (2) , A22. 10.1016/j.antiviral.2008.01.030 |
Abstract
Structure-based drug design methods utilize knowledge of a three-dimensional structure of an enzyme/receptor to develop small molecules able to bind to the desired target, generating a specific biological response. These computer-based methodologies are now becoming an integral part of the drug discovery process and, although the principles of molecular recognition are far from being completely understood, some marketed compounds (i.e. influenza neuraminidase inhibitors and HIV protease inhibitors) have been developed with a successful application of structure-based design techniques. In this presentation we are reporting a successful application of a computer-aided design approach to identify and synthetize a series of novel HCV helicase inhibitors. Initially a putative binding site was identified on the enzyme surface, then a de novo drug design software package was used to generate an initial set of structures that could potentially bind to it. A further structure refinement was carried out by docking a series of virtual libraries derived from the de novo procedure. The best structure identified in silico (AB100) was then prepared and it exhibits a submicromolar inhibition of the HCV helicase. The results of the replicon assay as well as the enzymatic assay for AB100 and a series of related analogues will be also presented.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Pharmacy Biosciences |
Publisher: | Elsevier |
ISSN: | 0166-3542 |
Last Modified: | 05 Jan 2024 05:54 |
URI: | https://orca.cardiff.ac.uk/id/eprint/6451 |
Citation Data
Actions (repository staff only)
Edit Item |